Lung cancer test for EGFR T790M mutation
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new blood test that can detect a specific genetic change (EGFR T790M) in advanced lung cancer. It aims to see if the test works well for guiding treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced non-small cell lung cancer (stage IIIB or IV).
- Your lung cancer has an EGFR mutation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses your tumor sample to guide personalized treatment decisions for certain lung cancers. It may help by matching you to a more targeted plan based on genetic testing and your prior treatment history.
This study looks at how well an EGFR-targeted pill (called an EGFR-TKI) works for people with advanced lung cancer that has an uncommon EGFR mutation. It may help doctors understand which patients benefit most and improve survival outcomes.
This study looks at how EGFR-mutated lung cancer changes over time and tries to find markers that can predict how well you might respond to treatment. You will provide a tumor sample for genetic analysis.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This trial tests a new drug called ANS02 in people with non-small cell lung cancer (a common type of lung cancer) that has a specific genetic change called an EGFR mutation. The drug is designed to target and slow cancer growth in people with this mutation.
This trial studies an oral (by mouth) EGFR-blocking medicine (DZD9008) in people with advanced lung cancer that has EGFR mutations. It’s for cancers that have grown despite standard treatment or couldn’t be tolerated, and aims to control the cancer while keeping side effects manageable.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.